Last $8.27 USD
Change Today -0.21 / -2.48%
Volume 377.5K
RPTP On Other Exchanges
As of 5:20 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

raptor pharmaceutical corp (RPTP) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/20/14 - $17.72
52 Week Low
05/9/13 - $5.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

raptor pharmaceutical corp (RPTP) Related Bloomberg News

View More Bloomberg News

raptor pharmaceutical corp (RPTP) Related Businessweek News

No Related Businessweek News Found

raptor pharmaceutical corp (RPTP) Details

Raptor Pharmaceuticals Corp., a biopharmaceutical company, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. It markets PROCYSBI, a delayed-release capsule used for the management of nephropathic cystinosis in adults and children six years and older in the United States. The company also commercializes PROCYSBI in the 28 member states of the European Commission plus Norway, Liechtenstein, and Iceland. Its clinical development products include RP103 used as a treatment for Huntington's disease; RP103 as a treatment for non-alcoholic fatty liver disease in children; and RP103 as a treatment for mitochondrial disorders, including Leigh syndrome. The company’s other clinical-stage product candidate is Convivia, an oral formulation of 4-methylpyrazole for the treatment of acetaldehyde toxicity resulting from aldehyde dehydrogenase deficiency. Its preclinical programs comprise cysteamine dioxygenase and HepTide for the treatment of hepatocellular carcinoma and other cancers susceptible to induced lysosomal storage. Raptor Pharmaceuticals Corp. has a collaboration agreement with DaVita Clinical Research to screen blood samples from the United States patients with end-stage renal disease to identify patients with unrecognized late-onset nephropathic cystinosis. The company was founded in 2005 and is headquartered in Novato, California.

70 Employees
Last Reported Date: 03/17/14
Founded in 2005

raptor pharmaceutical corp (RPTP) Top Compensated Officers

Co-Founder, Chief Executive Officer, Director...
Total Annual Compensation: $410.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $330.0K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $350.0K
Chief Business Officer
Total Annual Compensation: $292.0K
Chief Medical Officer and Chief Medical Offic...
Total Annual Compensation: $112.8K
Compensation as of Fiscal Year 2013.

raptor pharmaceutical corp (RPTP) Key Developments

Courtagen Life Sciences Announces Collaboration with Raptor Pharmaceuticals Inc. for Leigh Syndrome and Other Mitochondrial Disorders

Courtagen Life Sciences announced an agreement with Raptor Pharmaceuticals Inc. to provide genetic testing in the clinical trial for RP103 as a potential treatment for Leigh syndrome and other mitochondrial disorders. Leigh syndrome is a severe neurological disorder caused by genetic defects in mitochondrial or nuclear DNA affecting respiratory chain function that typically results in death within the first decade of life.

Raptor Pharmaceuticals Corp. Reports Audited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Earnings Guidance for the Year 2014

Raptor Pharmaceuticals Corp. reported audited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported net product sales of USD 10.248 million. Loss from operations was USD 10.669 million. Net loss was USD 12.091 million. Basic and diluted net loss per share was USD 0.20. Non-GAAP loss was USD 11.759 million or USD 0.19 per basic and diluted share. For the year, the company reported net product sales of USD 16.872 million. Loss from operations was USD 51.906 million compared to USD 17.934 million a year ago. Net loss was USD 69.417 million compared to USD 19.292 million a year ago. Basic and diluted loss per share was USD 1.20 compared to USD 0.37 a year ago. Non-GAAP loss was USD 51.640 million or USD 0.89 per basic and diluted share compared to USD 15.569 million or USD 0.30 per basic and diluted share a year ago. The company anticipates net product sales for PROCYSBI in the range of approximately USD 55 million to USD 65 million for 2014. On a non-GAAP basis, excluding non-cash stock-based compensation expense, operating expenses are expected to be in the range of USD 80 million to USD 90 million in 2014. The company's cash and cash equivalents are expected to be sufficient to fund operations through at least the first half of 2015, based on current operating plan assumptions.

Raptor Pharmaceuticals Corp., Q4 2013 Earnings Call, Mar 13, 2014

Raptor Pharmaceuticals Corp., Q4 2013 Earnings Call, Mar 13, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RPTP:US $8.27 USD -0.21

RPTP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RPTP.
View Industry Companies

Industry Analysis


Industry Average

Valuation RPTP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 30.9x
Price/Book 18.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.5x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RAPTOR PHARMACEUTICAL CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at